ABSTRACT
Objective To assess safety and efficacy of nusinersen in adult 5q spinal muscular atrophy (SMA) patients.
Methods Patients older than 15 years and followed at least for 6 months with one motor scale (Hammersmith Functional Motor Scale Expanded, HFMSE; Revised Upper Limb module, RULM) in five referral centers were included. Clinical and patients’ global impression of change (CGI-C and PGI-C) were recorded in treated patients at the last visit. Functional scales (Egen Klassification, EK2; Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, ALSFRS-R) and the percent-predicted forced vital capacity were collected when available.
Results Seventy-nine SMA patients (39 treated with nusinersen) were included. Compared with untreated patients, treated patients showed a significant improvement of 2 points (±0.46) in RULM (p<0.001) after six months. After a mean follow-up of 16 months, nusinersen treatment was associated with a significant improvement in HFMSE (OR=1.15, p=0.006), 6MWT (OR=1.07, p<0.001), and EK2 (OR=0.81, p=0.001).
Compared with untreated patients, more treated patients experienced clinically meaningful improvements in all scales, but these differences were statistically significant only for RULM (p=0.033), ALSFRS-R (p=0.005), and EK2 (p<0.001). According to the CGI-C and PGI-C, 64.1% and 61.5% of treated patients improved with treatment. Being non-sitter was associated with less response to treatment, while longer time of treatment was associated with better response. Most treated patients (77%) presented at least one adverse event, mostly mild.
Conclusions Nusinersen treatment associates to some improvements in adult SMA patients. Most severely affected patients with complex spines are probably those with the most unfavorable risk-benefit ratio.
Competing Interest Statement
Dr. Vazquez-Costa is funded by grants of the Instituto de Salud Carlos III (JR19/00030, PI Vazquez), served on advisory boards for Biogen and Roche and received travel and speaker honoraria from Biogen and Roche. Dr. Pitarch-Castellano served on advisory boards for Avexis and Biogen and received travel and speaker honoraria from Biogen and Roche; principal investigator for ongoing Biogen clinical trial. Dr.Nascimento-Osorio served on advisory boards for Roche, Avexis and Biogen and received travel and speaker honoraria from Biogen, Roche and Avexis; principal investigator for ongoing Biogen and Roche clinical trials. Dr. N. Muelas received travel honoraria from Biogen. Dr. A. Moreno received Speaker Honoraria from Biogen. Dr. M Povedano served on advisory boards for Roche and Biogen and received travel and speaker honoraria from Biogen.
Funding Statement
This study has received funding from FUNDAME (FUN-000-2017-01), from CUIDAME (PIC188-18), from Instituto de Salud Carlos III (JR19/00030 PI JFVC, 19/01178 PI TS), and from Generalitat Valenciana (PROMETEO/ 2018/135, PI TS). The Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER) is initiative from the ISCIII. TS and JFVC are members of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD). Sponsors did not participate in the study design, data acquisition and analysis, data interpretation or in writing the article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee for Biomedical Research of Instituto de Investigacion Sanitaria la Fe and Fundacio Sant Joan de Deu. All the participants gave written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data supporting our findings are available on reasonable request.
